ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Nov 18, 2017
Valuentum's Highest-Rated Economic Castles
Image Source: Dunrobin Castle; Golspie, Sutherland, John Haslam. A look at some of the highest-rated Economic Castles in our coverage universe.
Nov 17, 2017
How Have Our Best “Dividend Growth Ideas” Performed During 2017?
We wrote recently about how well the top-weighted ideas in the Best Ideas Newsletter portfolio have performed during 2017, but what about the top-weighted ideas in the other newsletter portfolio, the Dividend Growth Newsletter portfolio? How have they performed during 2017? Please tell us you know how well the top-weighted ideas have been performing.
Nov 17, 2017
Celgene Implodes
The pharma/biotech industry operates in a boom-bust environment where the market cap of a company can post a meteoric rise or suffer a precipitous fall based on the data published from recently completed clinical trials. The industry remains one of the most innovative fields, but the quest for new products leads to constant disruption and a subsequent spike in volatility. Of late, the volatility pendulum for Celgene has swung in favor of the bears with the company posting a costly phase 3 failure.
Nov 16, 2017
Cisco’s Shares Are Surging!
Image Source: Cisco. We received some fantastic news from newsletter portfolio idea Cisco. Shares are surging! Please tell me you knew that Cisco was one of our favorite ideas.
Nov 14, 2017
How Have Our “Best Ideas” Performed During 2017?
The top-weighted ideas are getting the job done, while we avoided one of the biggest missteps in all of 2017. We’ve had better years, but 2017 was still a great one.
Nov 14, 2017
GE Takes the Plunge, Halves Dividend
There may have been little surprise across the market when GE halved its dividend in its investor update November 13, but shares are selling off after management issued weaker-than-expected EPS guidance for 2018.
Nov 11, 2017
4 Burning Questions About Gilead Sciences
Image Source: Gilead. We were pleased with the jump in shares of Gilead Sciences following its recent addition to the newsletter portfolios. The equity has given back some of those gains more recently as questions have resurfaced on the vitality of the enterprise. In this article, we work through the top 4 questions for readers to consider in evaluating Gilead Sciences.
Nov 10, 2017
Could Sally Beauty Become Amazon’s “Whole Foods” Foray into Beauty Supply?
Image Source: Sally Beauty.  “The Amazon Effect” on traditional retail is not a new development, but there are some pockets of retail that were believed to be impenetrable by the e-commerce giant. We’re beginning to see that such a notion may have been nothing short of wishful thinking.
Nov 10, 2017
Qualcomm Surges to Fair Value on Broadcom Offer
Shares of Qualcomm have faced meaningful pressure for the majority of 2017 as it deals with a legal battle with Apple, but the stock has rallied after Broadcom offered the firm a deal worth $70 per share in cash and stock.
Nov 7, 2017
Michael Kors’ Stock Surges; Market Overreacts to Hanesbrands' Results
Image shown: Shares of Michael Kors have been rocketing higher recently. The stock is rated 9 on the Valuentum Buying Index. The sole 9 rating on the Valuentum Buying Index has had a very nice couple of months recently. Meanwhile, Hanesbrands is feeling the wrath of considerable selling pressure, and we don't think it is justified.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.